we got volume, and news!!
Sentiment: Strong Buy
and a down day on an up date for the market. Pharmainvestor, what's your take?
Disappointed with the stock price movement but Ph1 ARQ 092 trials is still going. So, it it too early to say much more at this time. ARQL will need to find a partner for 092.
The next is ASCO 2013 in early June. Abstracts will be released on May 15.
Hope to see ARQL stock around $3.5+ going into ASCO.